The Albanese Government has effectively rejected or obfuscated most of the committee's recommendations, but that does not mean the response has no value or cannot contribute to positive change. Stakeholders must understand the nuance and recognise the real opportunities because these processes never deliver the 'magic bullet'.
A minimalist but entirely predictable response - the opportunities are in the nuance
December 1, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech

